These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 28338171

  • 1. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L, Chen M, Chen J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar 25; 20(3):357-360. PubMed ID: 28338171
    [Abstract] [Full Text] [Related]

  • 2. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
    Oberg K.
    Endocr Relat Cancer; 2011 Oct 25; 18 Suppl 1():S17-25. PubMed ID: 22005113
    [No Abstract] [Full Text] [Related]

  • 3. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H.
    Am J Gastroenterol; 2015 Aug 25; 110(8):1223-32. PubMed ID: 26032155
    [Abstract] [Full Text] [Related]

  • 4. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M.
    Neuroendocrinology; 2017 Aug 25; 104(2):170-182. PubMed ID: 27078712
    [Abstract] [Full Text] [Related]

  • 5. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
    Singh S, Law C.
    Expert Rev Gastroenterol Hepatol; 2012 Jun 25; 6(3):313-34. PubMed ID: 22646254
    [Abstract] [Full Text] [Related]

  • 6. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
    Malczewska A, Witkowska M, Wójcik-Giertuga M, Kuśnierz K, Bocian A, Walter A, Rydel M, Robek A, Pierzchała S, Malczewska M, Leś-Zielińska I, Czyżewski D, Ziora D, Pilch-Kowalczyk J, Zajęcki W, Kos-Kudła B.
    Neuroendocrinology; 2021 Jun 25; 111(4):304-319. PubMed ID: 32335553
    [Abstract] [Full Text] [Related]

  • 7. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
    Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin AG, Chayvialle JA, Scoazec JY, Lombard-Bohas C.
    Eur J Cancer; 2012 Aug 25; 48(12):1766-73. PubMed ID: 22133573
    [Abstract] [Full Text] [Related]

  • 8. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.
    Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali A, Corleto VD, Annibale B, Buonadonna A, Pederzoli P, Delle Fave G.
    J Endocrinol Invest; 2004 Jan 25; 27(1):6-11. PubMed ID: 15053236
    [Abstract] [Full Text] [Related]

  • 9. Management of pancreatic neuroendocrine tumors.
    Dabizzi E, Panossian A, Raimondo M.
    Minerva Gastroenterol Dietol; 2010 Dec 25; 56(4):467-79. PubMed ID: 21139544
    [Abstract] [Full Text] [Related]

  • 10. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
    van Treijen MJC, van der Zee D, Heeres BC, Staal FCR, Vriens MR, Saveur LJ, Verbeek WHM, Korse CM, Maas M, Valk GD, Tesselaar MET.
    Neuroendocrinology; 2021 Dec 25; 111(6):586-598. PubMed ID: 32492680
    [Abstract] [Full Text] [Related]

  • 11. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, Peracchi M.
    Neuroendocrinology; 2014 Dec 25; 100(2-3):240-9. PubMed ID: 25428270
    [Abstract] [Full Text] [Related]

  • 12. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM.
    Endocrinol Metab Clin North Am; 2011 Mar 25; 40(1):111-34, viii. PubMed ID: 21349414
    [Abstract] [Full Text] [Related]

  • 13. [Chromogranin A and neuroendocrine tumors].
    Díaz Pérez JÁ, Currás Freixes M.
    Endocrinol Nutr; 2013 Mar 25; 60(7):386-95. PubMed ID: 23271036
    [Abstract] [Full Text] [Related]

  • 14. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
    Dittadi R, Gion M.
    Clin Biochem; 2013 Aug 25; 46(12):1145. PubMed ID: 23608355
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients.
    Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, Rau KM, Yeh KY, Chen TC, Sun CF.
    Neuroendocrinology; 2012 Aug 25; 95(4):344-50. PubMed ID: 22343505
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
    Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE, Peracchi M.
    Am J Gastroenterol; 2010 Sep 25; 105(9):2072-8. PubMed ID: 20372113
    [Abstract] [Full Text] [Related]

  • 20. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R, Libutti SK, Saif MW.
    JOP; 2013 Mar 10; 14(2):155-7. PubMed ID: 23474561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.